Random fresh urine and EDTA samples were collected from healthy individuals and volunteers with chronic kidney disease who gave their informed consent. EDTA samples were centrifuged immediately and aliquoted. All samples were maintained at -808C until analysis during the following 2 weeks. Precision was evaluated in accordance with the recommended CLSI EP-5A2 guideline: six urine samples (for the Architect) and seven EDTA plasma samples (for the Triage) pools were assayed in triplicate, once per day on five different days. The imprecision study thus consisted of 15 measurements for each pool, i.e., 90 determinations for urine and 105 for plasma. We also evaluated measurement uncertainty which characterizes the dispersion of the possible values around the ''true'' value, which is not always known and which is method and matrix-specific, the accuracy and the b-expectation limits. b-expectation tolerance limits with bs0.95 is the upper and lower values between which future measurements of the same level has a 95% probability of being found (7, 8) . The study was approved by the Institutional Review Board of the Centre Hospitalier Universitaire de Liège.
The results of the precision evaluation are shown in Table  1 . The coefficient of variation (CV) did not exceed 6% for the Abbott Architect NGAL. For the Biosite Triage, the CV ranged from 5% to 16% at concentrations of 722 and 117 mg/L, respectively. Measurement uncertainty and b-expectation tolerance limits are also shown in Table 1 . Measurement uncertainty ranged from 3.4% to 12.5% for the Abbott Architect vs. 10.4%-33.3% for the Triage. The b-expectation tolerance intervals were computed at each concentration level with a probability bs95%. In other words, on average 95% of future results generated by this method will be included in the computed tolerance intervals. Thus, the method will provide accurate results if the 95% b-expectation tolerance interval at each concentration level is fully included in the acceptance limits that we proposed of "20%. This is illustrated in Figure 1A using an error profile for the Abbott Architect, showing that this method provided precise results from 22.5 to 1315 mg/L. These two concentrations define the range of the method. Thus, it is guaranteed that future results will be included within "20% with a probability of 95%.
However, Figure 1B shows that the Biosite Triage NGAL method will provide precise results between 619 and 722 The standard deviation (SD) and coefficient of variation (CV) correspond to the total variability observed during the 5 days of the experiment. Uncertainty characterizes the dispersion of the values around the (unknown) true value. The b-expectation tolerance limits show, for each level tested, where 95% of future results generated by the methods could be situated.
Figure 1 Error profile of the Abbott Architect NGAL (A) and Biosite Triage NGAL (B)
. When the b-expectation limits (--) are comprised between the maximum total allowable error («) (shown here at "20%), the method is considered to be valid.
Each dot represents the result of one assay. As shown here, the Biosite Triage method is valid between 619 mg/L and 722 mg/L only, whereas the Abbott Architect method is valid through the whole measurement range studied.
mg/L. In this range only will result obtained with this method be within "20% of the actual value, with a probability of 95%.
We present the results of the analytical validation of two newly commercially available kits for NGAL measurements. The aim of our study was to compare the analytical performance of these assays. To the best of our knowledge, there is no publication on the analytical performances of the Biosite Triage NGAL. The analytical validation of the Abbott Architect NGAL was published recently by scientists employed by the Abbott Company (9). Our validation confirms the good performance of the assay, is independent of any company, and used an innovative method in the field of Clinical Chemistry (10) . The Abbott Architect NGAL is an automated method that needs to be used in the laboratory, whereas the Triage NGAL can be used at the bedside. For institutions that do not have the possibility to run the NGAL on the Architect, the Biosite Triage NGAL could be an alternative as the Triage meters can be used in a ward. Unfortunately, the analytical performance of this machine did not fulfil our expectations. Indeed, the method showed important analytical limitations, the primary one being the high variation around the proposed cut-off for the reference value (below urement using the cut-off value is thus questionable with the Triage NGAL which shows a high analytical variability around this cut-off value. Our results show that for a patient presenting with a value of 163 mg/L, the ''true value'' could range, with a confidence of 95%, between 109 and 221 mg/L with the Triage. In comparison, a urine value of 141 mg/L has a 95% confidence range between 125 and 158 mg/L.
Moreover, it must be remembered that this high variation was observed when the analyses were performed under optimal conditions, with a well-trained and experienced technician. In the hands of many different inexperienced nurses in a crowded ward, this variability could be worse.
The Abbott Architect NGAL assay gave much more precise results. Our results showed that between 22.5 and 1315 mg/L, 95% of the results will be within "20% maximum allowable total error, which is acceptable for an immunoassay.
Many publications have shown interest in NGAL as a potential new marker for the early detection of AKI (1) (2) (3) . These data, obtained with different ELISA methods, are somewhat difficult to translate directly into clinical practice. Our results show that when NGAL was determined in urine with the Abbott Architect, imprecision was less than when it was determined in plasma with the Triage method. From our ''analytical'' point of view, the Abbott Architect NGAL is, at present, the best method for detecting AKI.
